Several outlets are highlighting key FDA decisions expected in the third quarter, with a focus on oncology. The FDA is also considering easing restrictions on certain peptides, although the agency is currently experiencing leadership changes. The number and timing of specific FDA decisions to watch vary across reports, with some outlets looking ahead to the rest of 2026.